Home

AMARIN CORPORATION

Amarin Corporation is a late-stage biopharmaceutical company focused on improving the treatment of cardiovascular disease. Amarin is developing AMR101, a prescription-grade omega-3 fatty acid, as a prescription medicine for the treatment of patients with very high triglyceride levels (≥500 mg/dL) and as a potentially first-in-class therapy for patients with high triglyceride levels (≥200 and <500mg/dL) who are also on statin therapy for elevated LDL-cholesterol levels (mixed dyslipidemia).

Amarin's cardiovascular programs capitalize on Amarin's expertise in the field of lipid science and the known therapeutic benefits of essential fatty acids in treating cardiovascular disease.

AMR101 for Hypertriglyceridemia

AMR101 is prescription grade, ultra-pure (>96%) ethyl ester of eicosapentaenoic acid (ethyl-EPA; an omega-3 fatty acid). AMR101 is being positioned as a best-in-class prescription medicine for treating patients with high or very high triglycerides.

There is significant scientific and clinical evidence supporting the efficacy of ethyl-EPA in lowering triglyceride levels. AMR101 has been studied in over 1,000 patients in double-blind, placebo-controlled studies, including over 100 patients studied for greater than 12-months.

It is estimated that 40 million people in the US have elevated triglyceride levels, which are associated with the increased risk of developing coronary artery disease as well as being a component of certain other metabolic disorders, such as diabetes and obesity.

read more
Download